Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 27 for your search:

Cancer Type/Condition:  Soft tissue sarcoma, adult
Stage/Subtype:  stage II adult soft tissue sarcoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 20050113, NCT00243685

Phase III Study of Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiotherapy in Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI
Protocol IDs: COG-ARST0331, NCT00075582, ARST0331

Phase III Study of Risk-Based Therapy Comprising Observation Only, Adjuvant Radiotherapy, or Adjuvant Chemoradiotherapy or Neoadjuvant Chemoradiotherapy, Surgery, and Adjuvant Chemotherapy With or Without Radiotherapy in Young Patients With Non-Rhabdomyosarcoma Soft Tissue Sarcoma

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 30 at diagnosis
Sponsor: NCI
Protocol IDs: COG-ARST0332, ARST0332, NCT00346164

Phase III Randomized Study of Vincristine, Dactinomycin, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan Hydrochloride in Combination With Radiotherapy in Patients With Newly Diagnosed, Intermediate-Risk Rhabdomyosarcoma

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI
Protocol IDs: COG-ARST0531, NCT00354835, ARST0531

Phase I/II Study of Real Time Magnetic Resonance-Based Non-Invasive Thermometry in Patients With Grade 2 or 3 Soft Tissue Sarcoma of the Extremity Receiving Combination Hyperthermia, Radiotherapy, Surgery, and Optional Chemotherapy

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: DUMC-1308-04-7R5, DUMC-G040102, DUMC-G880018, NCT00093509

Phase I/II Study of Nelfinavir Mesylate in Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-04090, NCT00233948

Phase I/II Study of Neoadjuvant Conformal Radiotherapy and Sorafenib Tosylate Followed By Surgical Resection in Patients With Soft Tissue Sarcoma of the Extremity and Body Wall

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCDCC-216, UCDCC#216, BAYER-UCDCC-216, NCT00805727

Phase II Pilot Study of Irinotecan and Carboplatin as Upfront Window Therapy in Patients With Newly Diagnosed Intermediate- or High-Risk Rhabdomyosarcoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: MSKCC-03099, NCT00077285

Radiation Therapy to Treat Musculoskeletal Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992

10.

Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Other
Protocol IDs: UMCC 2004.010, NCT00189137

11.

Phase II Study of Bevacizumab In Patients With Newly Diagnosed or Recurrent/Refractory Angiosarcoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NU-04S1, NCT00288015

12.

Bevacizumab and Radiation Therapy for Sarcomas

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 05-090, 1 R21 CA117128-01A1, NCT00356031

13.

Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187

14.

Phase II Study of Neoadjuvant Image-Guided Radiotherapy in Patients With Primary Soft Tissue Sarcoma of the Extremity

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0630, RTOG 0630, NCT00589121

15.

Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas

Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293

16.

Proton RT for the Treatment of Pediatric Rhabdomyosarcoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: 04-188, NCT00592592

17.

Phase II Study of Neoadjuvant Intensity-Modulated Radiotherapy in Patients With Stage IB-III Soft Tissue Sarcoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-07216, 07216, NCT00740597

18.

Phase II Pilot Study of Neoadjuvant Sorafenib Tosylate and Ifosfamide in Patients With Resectable High-Grade Soft Tissue or Bone Sarcoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0704086, 07-04-086, BAYER-UCLA-0704086, ONYX-UCLA-0704086, NCT00880542

19.

Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: UFPTI 0803-SA02, NCT00881595

20.

Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UFPTI 0805-SA03, NCT00901836

21.

Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide

Phase: Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TRC105499, TRC105499, NCT00358540

22.

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-03740, NCT00580320

23.

Phase I Study of Neoadjuvant Therapy Comprising Sorafenib Tosylate, Epirubicin Hydrochloride, Ifosfamide, and Hypofractionated Radiotherapy Followed by Surgery in Patients With High-Risk Stage II or III Soft Tissue Sarcoma of the Extremity or Body Wall

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: OHSU-4653, OHSU-4653, 4653, OHSU-SOL-08080-L, BAYER-OHSU-4653, NCT00822848

24.

Randomized, Double Blind, Placebo-Controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 05-409, NCT00821652

25.

Adjuvant Valproate for High Grade Sarcomas

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AAAD4523, NCT01010958

Select All on Page

Help with Results

A Service of the National Cancer Institute